AVALO THERAPEUTICS, INC. Selling and Marketing Expense
AVALO THERAPEUTICS, INC. (AVTX) reported Selling and Marketing Expense of $2.80 million for the 3-month period ending 2022-06-30, per its 10-K filed 2023-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2023-05-04
- AVALO THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2022-06-30 was $2.80M, a 250.00% increase year-over-year.
- AVALO THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2022-03-31 was $1.90M, a 336.78% increase year-over-year.
- AVALO THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2021-12-31 was $826.00K, a 50.46% increase year-over-year.
- AVALO THERAPEUTICS, INC. selling and marketing expense for the quarter ending 2021-09-30 was $700.00K, a 51.52% increase year-over-year.
- AVALO THERAPEUTICS, INC. selling and marketing expense for fiscal 2021 was $2.83M, a 20.72% increase from fiscal 2020.
- AVALO THERAPEUTICS, INC. selling and marketing expense for fiscal 2020 was $2.34M, a 57.74% increase from fiscal 2019.
- AVALO THERAPEUTICS, INC. selling and marketing expense for fiscal 2019 was $1.48M, a 172.19% increase from fiscal 2018.
- AVALO THERAPEUTICS, INC. selling and marketing expense for fiscal 2018 was $545.22K, a 4.32% decline from fiscal 2017.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | $2.80M 10-K · filed 2023-03-29 | $4.70M derived: sum of 2 quarters · filed 2023-05-04 | $5.53M derived: sum of 3 quarters · filed 2023-05-04 | $6.23M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-04 | $1.93M 10-Q · filed 2022-05-05 | $2.73M derived: sum of 2 quarters · filed 2023-05-04 | $3.43M derived: sum of 3 quarters · filed 2023-05-04 | $4.23M derived: sum of 4 quarters · filed 2023-05-04 | |||
| 2021-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $1.53M derived: sum of 2 quarters · filed 2022-11-07 | $2.33M derived: sum of 3 quarters · filed 2022-11-07 | $2.83M 10-K · filed 2022-03-02 | ||||
| 2021-09-30 | $700.00K 10-Q · filed 2022-11-07 | $738.00K 10-Q · filed 2021-11-09 | $1.50M derived: sum of 2 quarters · filed 2022-11-07 | $2.00M 10-Q · filed 2022-11-07 | $1.96M 10-Q · filed 2021-11-09 | $2.48M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $800.00K 10-Q · filed 2022-08-04 | $786.00K 10-Q · filed 2021-08-02 | $1.20M 10-Q · filed 2022-08-04 | $1.22M 10-Q · filed 2021-08-02 | $1.78M derived: sum of 3 quarters · filed 2022-08-04 | $2.25M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $435.00K 10-Q · filed 2022-05-05 | $984.00K derived: sum of 2 quarters · filed 2022-05-05 | $1.45M derived: sum of 3 quarters · filed 2022-05-05 | $2.10M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $1.01M derived: sum of 2 quarters · filed 2022-03-02 | $1.66M derived: sum of 3 quarters · filed 2022-03-02 | $2.34M 10-K · filed 2022-03-02 | $2.34M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $462.00K 10-Q · filed 2021-11-09 | $462.32K 10-Q · filed 2020-11-09 | $1.11M derived: sum of 2 quarters · filed 2021-11-09 | $1.79M 10-Q · filed 2021-11-09 | $1.79M 10-Q · filed 2020-11-09 | $2.34M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $653.00K 10-Q · filed 2021-08-02 | $653.26K 10-Q · filed 2020-08-06 | $1.33M 10-Q · filed 2021-08-02 | $1.33M 10-Q · filed 2020-08-06 | $1.88M derived: sum of 3 quarters · filed 2021-08-02 | $2.09M derived: sum of 4 quarters · filed 2021-08-02 | ||
| 2020-03-31 | $677.00K 10-Q · filed 2021-05-13 | $676.53K 10-Q · filed 2020-05-07 | $1.22M derived: sum of 2 quarters · filed 2021-05-13 | $1.44M derived: sum of 3 quarters · filed 2021-05-13 | $1.76M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $547.70K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $761.91K derived: sum of 2 quarters · filed 2021-03-08 | $1.09M derived: sum of 3 quarters · filed 2021-03-08 | $1.48M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $214.21K 10-Q · filed 2020-11-09 | $2.63M 10-Q · filed 2019-11-14 | $540.07K derived: sum of 2 quarters · filed 2020-11-09 | $936.34K 10-Q · filed 2020-11-09 | $8.68M 10-Q · filed 2019-11-14 | -$4.41M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $325.86K 10-Q · filed 2020-08-06 | $2.94M 10-Q · filed 2019-08-08 | $722.14K 10-Q · filed 2020-08-06 | $6.05M 10-Q · filed 2019-08-08 | -$4.62M derived: sum of 3 quarters · filed 2020-08-06 | -$2.31M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $396.28K 10-Q · filed 2020-05-07 | $3.11M 10-Q · filed 2019-05-09 | -$4.95M derived: sum of 2 quarters · filed 2020-05-07 | -$2.64M derived: sum of 3 quarters · filed 2020-05-07 | -$594.87K derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | -$5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$3.03M derived: sum of 2 quarters · filed 2020-03-11 | -$991.14K derived: sum of 3 quarters · filed 2020-03-11 | $545.22K 10-K · filed 2020-03-11 | $8.52M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $2.31M 10-Q · filed 2019-11-14 | $4.35M derived: sum of 2 quarters · filed 2019-11-14 | $5.89M 10-Q · filed 2019-11-14 | $6.85M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $2.04M 10-Q · filed 2019-08-08 | $3.58M 10-Q · filed 2019-08-08 | $4.54M derived: sum of 3 quarters · filed 2019-08-08 | $4.54M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $1.52M 10-Q · filed 2019-05-09 | $2.50M derived: sum of 2 quarters · filed 2019-05-09 | $2.50M derived: sum of 3 quarters · filed 2019-05-09 | $2.50M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $973.00K 10-K · filed 2018-04-02 | $973.00K derived: sum of 2 quarters · filed 2018-11-13 | $973.00K derived: sum of 3 quarters · filed 2018-11-13 | $569.83K 10-K · filed 2019-03-18 | $973.35K 10-K · filed 2018-04-02 | |||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | $0.00 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |